🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Health Concern

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million instances each year. Notably increased rates are seen in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the management of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

As per data released by a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This places it at an comparable level with the existing first-line therapy, which uses an injection and a pill. The study included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have voiced optimism. The availability of a easy-to-administer therapy like this is seen as a "revolutionary step" for public health efforts. This is considered vital to alleviate the strain of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.